<DOC>
	<DOCNO>NCT00710762</DOCNO>
	<brief_summary>The primary objective study estimate Progression Free Survival Rates ( PFS ) patient relapsed ovarian cancer 9 month continuous treatment either BIBF 1120 match placebo .</brief_summary>
	<brief_title>A Randomised Placebo-Controlled Phase II Study Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy Patients With Relapsed Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Female patient histologically confirm advanced ovarian carcinoma , fallopian tube carcinoma primary peritoneal cancer serous type recurrent disease respond 2nd , 3rd 4th line chemotherapy . Response define either confirm decline CA125 least 50 % pretreatment value Objective Response , i.e . Partial Response ( PR ) Complete Response ( CR ) accord RECIST criterion patient measurable disease . Treatmentfree interval &lt; 12 month since commence prior treatment regimen relapse ovarian cancer . Full recovery therapy relate toxicity previous chemotherapy radiotherapy recovery much improvement may expect investigator . Age &gt; 18 year . Life expectancy least 3 month . ECOG Performance Score &lt; 2 . Adequate hepatic function : total bilirubin 26Âµmol/L , ALT and/or AST 1.5x upper limit normal ( ULN ) . INR , Prothrombin time ( PT ) partial thromboplastin time ( PTT ) : maximum 50 % deviation normal limit . Adequate renal function : serum creatinine 1.5 x ULN . Absolute neutrophil count ( ANC ) &gt; 1.5 x 109l , Platelets &gt; 100 x 109/l , Haemoglobin &gt; 9.0 g/dl . Written inform consent consistent ICHGCP guideline . Minimum time elapse since last chemotherapy ( include hormonal treatment Hormone Replacement Therapy [ HRT ] ) immunotherapy first administration BIBF 1120 must 4 le 8 week . Serious illness concomitant nononcological disease neurologic , psychiatric , infectious disease active ulcer ( gastrointestinal tract , skin ) laboratory abnormality may increase risk associate study participation study drug administration judgment investigator would make patient inappropriate entry study . Major injury and/or surgery within past 4 week incomplete wound heal bone fracture plan surgical procedure study period . Hypersensitivity BIBF 1120 excipients study drug . Significant cardiovascular disease ( i.e . uncontrolled hypertension , unstable angina , history infarction within past 9 month , congestive heart failure &gt; NYHA II ) . History haemorrhagic thrombotic event past 12 month . Known inherited predisposition bleeds thrombosis . Patients require fulldose anticoagulation . Gastrointestinal disorder abnormality would inhibit absorption study drug . Brain metastases leptomeningeal disease . Treatment investigational drug participation another clinical trial within past four week start therapy concomitantly trial . Chemo , radio , immunotherapy within past four week prior treatment trial drug . Patients unable comply protocol . Active alcohol drug abuse . Other documented malignancy exception nonmelanomatous skin cancer within past 5 year . Patients clinically sterile .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>